JAC Advance Access originally published online on January 16, 2004
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Journal of Antimicrobial Chemotherapy (2004) 53, 403
© 2004 The British Society for Antimicrobial Chemotherapy
Correspondence |
Reply
Institute of Medical Microbiology and Hygiene, Johannes Gutenberg-University, Augustusplatz/Hochhaus, D-55101 Mainz, Germany
Sir,
We thank Dr Dugue for his interest in our recent publication.1 It was not our intention to justify our study by the statement in the Introduction that no effective treatment for cryptosporidiosis is currently available. The objective of the study was to test a direct effect of several protease inhibitors used in the treatment of AIDS patients as part of HAART on parasite development in vitro.
We are in agreement with Dr Dugue that the recent approval of nitazoxanide for the treatment of cryptosporidiosis in children by the US Food and Drug Administration is a substantial improvement in the situation and we hope that the drug will also be approved for adults, and especially AIDS patients, in the near future.
Footnotes
* Corresponding author. Tel: +49-6131-393-3139; Fax: +49-6131-393-3439; E-mail: fpetry{at}mail.uni-mainz.de ![]()
References
1
.
Hommer, V., Eichholz, J. & Perry, F. (2003). Effect of antiretroviral protease inhibitors alone, and in combination with paromomycin, on the excystation, invasion and in vitro development of Cryptosporidium parvum. Journal of Antimicrobial Chemotherapy 52, 35964.
![]()
CiteULike
Connotea
Del.icio.us What's this?
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||